A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

Investigational New Drugs

Volumn 22, Issue 4, 2004, Pages 437-448

  Schwartz, Garry H ^a   Jones, Christopher B ^a   Garrison, Mitchell ^a   Patnaik, Amita ^b   Takimoto, Chris ^b   McCreery, Heather ^b   Skinner, Michael ^c   Tolcher, Anthony W ^b   Rowinsky, Eric K ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

antifolate; docetaxel; phase I study; polyglutamate; thymidylate synthase; ZD9331

Indexed keywords

CORTICOSTEROID; DOCETAXEL; FOLIC ACID ANTAGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST; PLEVITREXED; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZM 257589;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERANCE; FEMALE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OBSERVATION; OVARY CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; TAXOIDS; THYMIDYLATE SYNTHASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 10244265976     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000036686.86700.a9     Document Type: Article

References (44)

1. Jackman AL, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6: 871-881, 1995
2. Jackman AL, Judson IR: The new generation of thymidylate synthase inhibitors in clinical study. Exp Opin Invest Drugs 5: 719-736, 1996
3. Rustum YM, Harstrick A, Cao S, et al.: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1987; 15: 389-400, 1997
4. Touroutoglou N, Pazdur R: Thymidylate synthase inhibitors. Clin Cancer Res 2: 227-243, 1996
5. Rhee MS, Wang Y, Nair MG, Galivan J: Acquisition of resistance to antifolates caused by enhaced γ-glutamyl hydrolase activity. Cancer Res 53: 2227-2230, 1993
6. Pizzorno G, Mini E, Coronnello M, et al.: Impaired polyglutamation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high dose treatment with this drug. Cancer Res 48: 2149-2155, 1988
7. McCloskey DE, McGuire JJ, Russell CA, et al.: Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266: 6181-6187, 1991
8. Jackman AL, Kelland LR, Kimbell, R, et al.: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex), in one mouse and three human cell lines. Br J Cancer 71: 914-924, 1995
9. Li WW, Waltham M, Tong W, Schweitzer BI, Bertino JR: Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. In: Ayling JE, Nair MG, Baugh CM (eds) Chemistry and Biology of Pieridines and Folates, Advances in Experimental Medicine and Biology. Vol. 338, New York: Plenum 1993, pp. 635-638
10. Wardleworth JM, Boyle JF, Jackman AL, et al.: ZD9331, the design and synthesis of a novel non-polyglutamatable TS inhibitor. Ann Oncol 5(Suppl 5): 247, 1994
11. Jackman AL, Kimbell R, Brown M, et al.: The antitumor activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol 370: 185-188, 1994
12. Boyle FT, Stephens TC, Averbuch SD, Jackman AL.: ZD9331: Preclinical and clinical studies. In Jackman AL (ed) Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa NJ: Humana Press Inc., pp. 243-260
13. Aherne GW, Hardcastle A., Ward E, et al.: Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clin Can Res 7: 2923-2930, 2001
14. Jackman AL, Kimbell R, Aherne GW, et al.: Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Can Res 3: 911-921, 1997
15. Jackson RC, Jackman AL, Calvert AH: Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lymphoblastoid cells. Biochem Pharmacol 32: 3783-3790, 1983
16. Jackman AL, Taylor GA, Gibson W, et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: new agent for clinical study. Cancer J Res 51: 5579-5586, 1991
17. Jackman AL, Farrugia DC, Gibson W, et al.: ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J Cancer 31A: 1277-1282, 1995
18. Jackman AL, Judson IR. The new generation of thymidylate synthase inhibitors in clinical study: Oncologic, endocrine and metabolic. Exp Opin Investig Drugs 5: 719-736, 1996
19. Jackman AL, Kelland LR, Kimbell R, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71914-71924, 1995
20. Jackman AL, Taylor GA, Calvert AH, et al. Modulation of antimetabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitors, CB3717. Biochem Pharmacol 33: 3269-3275, 1984
21. Clarke SJ, Jackman AL, Judson IR: The history of the development and clinical use of CB3717 and ICI D1694. Adv Exp Med Biol 339: 277-287, 1993
22. Stephens TC, Smith MN, McCloskey ML: ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor: In vivo antitumour efficacy and toxicity to normal murine tissues. Proc Am Assoc Cancer Res 35: 305, 1994 (abstract)
23. Goh BC, Ratain M, Bertucci D, et al.: Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin One 19: 1476-1484, 2001
24. Diab S, Britten C, Eckhardt G, et al.: Phase I and pharmacokinetic study of the nonpolyglutaminate thymidylate synthase inhibitor ZD9331 on a 30 minute infusion every 3 week schedule. Proc Am Soc Clin Oncol 17: 226, 1998, (abstract)
25. Rees C, Beale P, Trigo JM, et al.: Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clin Cancer Res 9: 2049-2055, 2003
26. Plummer R, Rees C, Hughes A, et al.: Phase I trial of ZD9331, a water-soluble, non-polyglutamatable thymidylate synthase inhibitor. Clin Cancer Res 9: 1313-1322, 2003
27. Ford HER, Mitchell F, Cunningham D, et al.: Patterns of elevation of plasma 2′deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8: 103-109, 2002
28. Rader JS, Clarke-Pearson D, Moore M, et al.: A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol 91: 318-325, 2003
29. Hainsworth J, Vergote I, Janssens J: A review of phase II studies of ZD9331 treatment for relapsed and refractory solid tumors. Anticancer Drugs 14(Suppl 1): S13-S19, 2003
30. Petruzelka L: Phase II multicenter trial of ZD9331 monotherapy as first-line treatment for gastric cancer. Anticancer Drugs 14(Suppl 1):S7-S12, 2003
31. Smith D, Gallagher N.: A phase II/III study comparing ZD9331 with gemcitabine in patients with pancreatic cancer. Eur J Cancer 39: 1377-1383, 2003
32. Rizzo JD, Villalona-Calero M, Garrison M, et al. A pharmacologic and metabolic study of docetaxel administered on a continuous weekly schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 162, 2003 (abstract)
33. Cortes JE: Pazdur R. Docetaxel. J Clin Oncol 13: 2643-2655, 1995
34. Bruno R, Vivier N, Veyrat-Follet C, et al.: Population pharmacokinetics and pharmacokinetic-pharmadynamic relationships for docetaxel. Invest New Drugs 19: 163-169, 2001
35. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36: 99-114, 1999
36. Sawyers MB, Ratain MJ, Bertucci D, et al: Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol 21: 1859-1865, 2003
37. de Jonge MJA, Glimelkius B, Verweij J, et al.: Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anti-Cancer Drugs 13: 645-643, 2004
38. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, et al.: Design of thymidylate synthase inhibitor using protein crystal structures: The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36: 733-745, 1993
39. Walton MI, Mitchell F, Aherne GW, et al.: The renal effects of the water soluble non-folylpolyglutamate synthase dependent thymidylate synthase inhibitor, ZD9331, in mice. Br J Can 78: 1457-1463, 1998
40. Adachi II, Taguchi T: The clinical utility of docetaxel in adriamycin-resistant breast cancer. Breast Cancer 4: 273-279, 1997
41. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T: Phase JJ trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 5: 1649-1655, 1996
42. Theti D, Jackman AL: The role of α-folate receptor-mediated transport in the antiumor activity of antifolate drugs. Clin Cancer Res 10: 1080-1089, 2004
43. Tomassetti A, Mangiarotti F, Mazzi M, et al.: The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human α-folate receptor gene in ovarian cancer. Cancer Res 63: 696-704, 2003
44. Leamon CP, Low PS: Folate-mediated targeting: From diagnostics to drug and gene delivery. Drug Discovery Today 6: 44-51, 2001